GNPX (Genprex) Common Stock : $0.01 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Genprex Common Stock?

Genprex's quarterly common stock increased from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($0.00 Mil) and increased from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.01 Mil).

Genprex's annual common stock declined from Dec. 2021 ($0.05 Mil) to Dec. 2022 ($0.00 Mil) but then stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

Genprex Common Stock Historical Data

The historical data trend for Genprex's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genprex Common Stock Chart

Genprex Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.02

0.04

0.05

Genprex Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Common Stock	Get a 7-Day Free Trial															0.06	-	-	-	0.01

Genprex Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Genprex Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genprex Inc (NAS:GNPX) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

0A8I:UK

Address

3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746

Website

https://www.genprex.com

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Executives

Catherine M Vaczy	officer: EVP & Chief Strategy Officer	C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
John Rodney Varner	director, 10 percent owner, officer: Chief Executive Officer	P.O. BOX 162341, AUSTIN TX 78716
Hermant Kumar	officer: Chief Mfgr & Tech Officer	3300 BEE CAVE ROAD, #650-227, AUSTIN TX 78746
Mark Stanley Berger	officer: Chief Medical Officer	140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Brent M Longnecker	director	C/O RESOURCES CONNECTION, 695 TOWN CENTER DR, COSTA MESA CA 92626
Moreno Toscano Jose Antonio	director	1501 UNIVERSITY CLUB DRIVE, AUSTIN TX 78732
Wilson William R Jr.	director	1407 ETHRIDGE AVE, AUSTIN TX 78703
Michael Thomas Redman	officer: EVP & Chief Operating Officer	16402 EMILIA COURT, SPRING TX 77379
John N Bonfiglio	director	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Genprex, Inc.	director, 10 percent owner, officer: Chief Executive Officer	1601 TRINITY STREET, BLDG. B, SUITE 3.322, AUSTIN TX 78712
Julien L Pham	officer: Chief Operating Officer	944 DORCHESTER AVE #56, BOSTON MA 02125
Jack A Roth	10 percent owner	6516 BROMPTON ROAD, HOUSTON TX 770055
Christy M. Nance	10 percent owner	8305 SCENIC RIDGE COVE, AUSTIN TX 78735
Ryan M. Confer	officer: Chief Financial Officer	1000 SAN MARCOS ST. #460, AUSTIN TX 78702
Robert W. Pearson	director	3001 MEANDERING RIVER COURT, AUSTIN TX 78746